Pancreatic cancer remains a major cause of death in western populations. Despite many efforts, little is known about its aetiology ([Malats, 2001](#bib19){ref-type="other"}). Several risk factors have been implicated: male gender, black race, cigarette smoking, diabetes mellitus and meat and fat consumption ([Sakorafas *et al*, 2000](#bib29){ref-type="other"}; [Sternheim *et al*, 2000](#bib35){ref-type="other"}; [Simon and Printz, 2001](#bib31){ref-type="other"}).

Ductal adenocarcinoma of the pancreas is a highly aggressive tumour with an early tendency of spreading to other organs ([Hermanek, 1998](#bib9){ref-type="other"}). Pancreatic cancer has a poor prognosis. The median survival is less than 6 months. The overall 5-year survival of 3% associated with pancreatic cancer is largely a result of diagnosis late in the course of the disease. Surgical resection remains the only chance for cure in patients with pancreatic cancer, but only 15--20% of patients have lesions that are resectable at the time of diagnosis. Current postresection 5-year survival rates are approximately 20% ([Wong *et al*, 2001](#bib41){ref-type="other"}). Conventional tumour markers, such as CA 19-9, have a high diagnostic sensitivity (80--90%), but lack a specifity (50--70%) and are therefore not suited for detecting early tumours ([Berndt *et al*, 1998](#bib3){ref-type="other"}; [Lamerz, 1999](#bib14){ref-type="other"}; [Wenger *et al*, 1999](#bib40){ref-type="other"}). More effective screening techniques are urgently needed to improve the poor prognosis of the disease ([Mizumoto and Tanaka, 2002](#bib21){ref-type="other"}).

Pancreatic cancer is among the best-described genetic diseases ([Hilgers and Kern, 1999](#bib10){ref-type="other"}). The development and growth of pancreatic adenocarcinoma involves oncogene activation, loss of tumour suppressor gene function and overexpression of receptor-ligand systems ([Goggins *et al*, 1999](#bib8){ref-type="other"}; [Efthimiou *et al*, 2001](#bib6){ref-type="other"}; [Shi *et al*, 2001](#bib30){ref-type="other"}). The Ki-ras oncogene is one of the three members of the human ras gene family that code for the highly related 21-kDa proteins with guanosine triphosphatase (GTPase) activity. Naturally occurring mutations in the Ki-ras gene have been localised to codon 12 (most frequently), 13 and 61. Owing to an associated inappropriate stimulation signal, the mutant ras transmits a constitutive growth signal to the nucleus ([Gansauge *et al*, 1996](#bib43){ref-type="other"}; [Olson and Marais, 2000](#bib25){ref-type="other"}). The incidence of ras gene mutations varies among different kinds of tumours, but was found mutated predominantly in pancreatic adenocarcinomas with a frequency of 80--90% ([Sirivatanauksorn *et al*, 1998](#bib32){ref-type="other"}; [Ghaneh *et al*, 2002](#bib7){ref-type="other"}).

Gene alterations of the ras type can be used as molecular markers to screen for the presence of neoplastic cells in different clinical specimens. Enriched PCR methods are able to discriminate mutant from wild-type alleles and also provide a high degree of sensitivity to detect mutant alleles in a large excess of normal DNA. Two PCR-based techniques have been most commonly used: ASA-PCR (allele-specific amplification), which is restricted to the analysis of individual codon-specific mutations and requires several allele-specific oligonucleotides, and the time-consuming RFLP-PCR (restriction fragment length polymorphism), which bears an increasing risk of *Taq* polymerase-born infidelity ([Weber, 1990](#bib39){ref-type="other"}; [Kahn *et al*, 1991](#bib13){ref-type="other"}; [Takeda *et al*, 1993](#bib36){ref-type="other"}; [Jacobson and Mills, 1994](#bib12){ref-type="other"}; [Mora *et al*, 1998](#bib22){ref-type="other"}).

More recently, the mutation-sensitive hybridisation profile of peptide nucleic acids (PNAs) has been exploited to design novel protocols (PCR-clamping). PNAs are none extendable oligonucleotides where the ribose-phosphate backbone is completely replaced by (2-aminoethyl)-glycine units linked by amide bonds. These synthetic oligomers bind with higher thermal stability to complementary nucleic acids than DNA and RNA. On the other hand, the PNA/DNA duplex is significantly destabilised in the case of single-base mismatch ([Ørum *et al*, 1993](#bib26){ref-type="other"}; [Ratilainen *et al*, 1998](#bib27){ref-type="other"}). In PNA-mediated PCR clamping, PNA oligomers suppress amplification of the wild-type sequence confined by a pair DNA oligonucleotide primers (competetive clamping) because PNA oligomers are no substrate for DNA polymerases. In the case of a single-base mismatch, the DNA/PNA duplex is destabilised, which allows strand elongation from bound DNA oligomer to proceed, resulting in the detection of PCR fragments, most of which harbour the variant allele, and the suppression of wild-type genomic sequences during amplification, respectively. This approach has been described for the detection of Ki-ras and p53 point mutations ([Thiede *et al*, 1996](#bib38){ref-type="other"}; [Behn *et al*, 2000](#bib2){ref-type="other"}).

Analysis of PCR products via mutation-specific hybridisation probes guarantees the most specific measurement of amplified target sequences. Hybridisation probes consists of two terminally fluorescent-labelled oligomers. Only after binding to the target sequence in close proximity, fluorescence resonance energy transfer (FRET) occur ([Lay and Wittwer, 1997](#bib15){ref-type="other"}) and the real-time fluorescence can be monitored. Hybridisation probes are furthermore suitable for experiments in which the amplification products formed are subsequently quantified using the evaluation software. The combination of detection by internal hybridisation probes and subsequent melting curve analysis expands the spectrum to include mutation analysis by rapid genotyping. One mismatch only, due to a single point mutation, between the internal hybridisation probes and their target sequences, can drastically change the melting temperature of the bound probe ([Lyon, 2001](#bib17){ref-type="other"}). In a recent study, the PNA-mediated PCR clamping method was combined with on-line detection for c-kit proto-oncogene point mutations ([Sotlar *et al*, 2003](#bib33){ref-type="other"}).

In the present study, we combined the PCR-clamping approach using a wild-type PNA (17-mer) with real-time PCR using mutant-specific hybprobes in single closed LightCycler capillaries. As a preliminary study, plasma and tissue samples of patients with pancreatic cancer were analysed with respect to point mutations in codon 12 of the Ki-ras proto-oncogene by melting point analysis.

MATERIAL AND METHODS
====================

Patients
--------

A total of 64 sera from 10 patients (seven male, three female) with pancreatic carcinoma (resectable and nonresectable) were analysed for Ki-ras mutation. In addition, four tissue samples from nonrelated pancreatic tumours were analysed for Ki-ras mutation.

Cell lines
----------

Cells of the cell line SW 480 (colon carcinoma) harbouring a homozygous Ki-ras codon 12 mutation were cultured in RPMI 1640 medium (50 ml culture flask) supplemented with 10% (v v^−1^) heat-inactivated fetal calf serum and 100 *μ*g ml^−1^ streptomycin (humidified atmosphere, 5% CO~2~, 37°C). Adherent cells were trypsinised and washed once with PBS solution (phosphate-buffered saline).

DNA extraction from the plasma
------------------------------

Blood samples (9 ml) were withdrawn from a peripheral vein and placed in tubes containing EDTA. The collected samples were centrifuged at 1500 r.p.m. for 10 min (Minifuge RF, Heraeus, Hanau, Germany). Plasma was stored at −20°C until further use. DNA was extracted from plasma with QIAamp spin columns (QIAamp DNA Mini Kit, Qiagen, Hilden, Germany) according to the manufacturer\'s instruction. Incubation with proteinase K was performed for 10 min at 68°C. Extracted DNA from 200 *μ*l of plasma was eluted with 50 *μ*l and stored at −20°C.

Isolation of DNA from paraffin-embedded tissue
----------------------------------------------

Tumour tissues were obtained at surgery and fixed with paraffin. DNA was extracted from tissue with QIAamp spin columns (QIAamp DNA Mini Kit) according to the manufacturer\'s instruction. In brief, not more than 25 mg of paraffin-embedded tissue was placed into a 2 ml microcentrifuge tube. Removal of paraffin was ensured by adding and mixing 1200 *μ*l xylene. After centrifugation at full speed for 5 min at room temperature, the supernatant was carefully removed and 1200 *μ*l of ethanol (96--100%) was added to the pellet. The mixture was centrifuged at full speed for 5 min at room temperature; afterwards, the ethanol was carefully removed. To remove residual xylene completely, the procedure was repeated. The open microcentrifuge tube was incubated at 37°C for 10--15 min until the ethanol had evaporated and the DNA was extracted was with QIAamp spin columns (QIAamp DNA Mini Kit, Qiagen, Hilden, Germany) according to the manufacturer\'s instruction. Lysis in the presence of proteinase K was overnight at 56°C. AL (200 *μ*l) buffer was added and mixed. DNA was eluted with 100 *μ*l of AE buffer and stored at −20°C.

Isolation of DNA from SW480 cells
---------------------------------

Cells were resuspended in 200 *μ*l of PBS solution. After adding 20 *μ*l proteinase K and 200 *μ*l AL buffer, the mixture was incubated at 56°C for 10 min. DNA extraction was continued as with tumour tissue (see above).

Real-time PCR and melting curve analysis
----------------------------------------

Real-time PCR was performed in a final volume of 20 *μ*l containing 10 m[M]{.smallcaps} TRIS-HCl pH 8.3, 50 m[M]{.smallcaps} KCl, 3.75 m[M]{.smallcaps} MgCl~2~, 125 *μ*[M]{.smallcaps} of each desoxynucleotide triphospate (Invitrogen, Carlsbad, USA), 1 *μ*[M]{.smallcaps} of primer Ki-ras F (5′-AAG GCC TGC TGA AAA TGA CTG-3′) and 1 *μ*[M]{.smallcaps} Ki-ras R (5′-GGT CCT GCA CCA GTA ATA TGC A-3′), 0.3 *μ*[M]{.smallcaps} hybridisation probe Ki-ras FL (donor) labelled on its 3′-end with fluorescein (5′-CGT CCA CAA AAT GAT TCT GAA TTA GCT GTA TCG TCA AGG CAC T-F-3′) and 0.3 *μ*[M]{.smallcaps} Ki-ras LC (acceptor) labelled on its 5′-end with the fluorescence dye LightCycler™-Red 640 (5′-LC Red640-TTG CCT ACG CCA ACA GCT CCA A-P-3′), 2.5 *μ*[M]{.smallcaps} PNA 17 mer (5′-CCT ACG CCA CCA GCT CC-3′), Protein Amplifly and 1.25 U of Platinum *Taq* DNA polymerase (Invitrogen). After an initial denaturation step at 95°C for 3 min, 45 cycles were performed with each cycle consisting of: denaturation at 95°C for 10 s, PNA annealing at 76°C for 7 s, annealing of the primers and probes at 60°C for 15 s and elongation at 72°C for 20 s. PCRs were carried out on the LightCycler Instrument (Roche Diagnostics, Mannheim, Germany).

Melting curve analysis was performed at steadily increasing temperature from 40 to 85°C with a transition rate of 0.3°C s^−1^. Fluorescence data obtained were analysed using the LightCycler software (software version 3.5, Roche Diagnostics).

Enriched *Bst*NI RFLP/PCR
-------------------------

Enriched *Bst*NI RFLP/PCR was confirmed as described elsewhere ([Mora *et al*, 1998](#bib22){ref-type="other"}). Digestion of the amplified products with the restriction enzyme *Bst*NI (New England BioLabs, Beverly, USA) was performed according to the manufacturer\'s instruction. After two rounds of PCR (heminested PCR) and digestions of the amplified DNA, all PCR products were electrophoresed in a 3% agarose gel (low melting point agarose) and the mutant allele (143-bp band) and the wild-type allele (114-bp band) was visualised by ethidium bromide staining (0.5 mg ml^−1^). All synthetic oligonucleotides used were purchased from TIB Molbiol (Berlin, Germany).

RESULTS
=======

Determination of interassay variability and optimisation of PNA concentration
-----------------------------------------------------------------------------

For detection of the hot spot point mutation of the Ki-ras proto-oncogene at codon 12, we used PNA-mediated PCR-clamping and real-time PCR with mutant-specific hybridisation probes. The relative positions of primers, hybridisation probes and PNA are shown in [Figure 1](#fig1){ref-type="fig"} (Genbank accession no. K01519; nucleotid positions 1--164). For PNA and hybprobes, the antisense strand was chosen due to the lower purine content to reduce mismatches. After optimising the PCR conditions, the interassay variability of the melting temperatures was determined. For wild-type and valine-mutated DNA, the variability was 68.0°C±0.8 (*n*=15) and 71.2°C±0.8 (*n*=15), respectively, and therefore allows precise discrimination of wild-type and mutant DNA by melting point analysis.

In appropriate clinical samples the proportion of malignant or premalignant to normal cells is extremely low. As shown in [Figure 2](#fig2){ref-type="fig"}, the melting points of 100 pg of mutant DNA extracted from SW 480 colon carcinoma cells in the presence of 1 *μ*g of wild-type DNA (1 : 10 000) were not detectable (curve 2 and 4). However now, in the presence of PNA, the wild-type-specific peak disappears and the mutant allele was detectable in a 1 : 10 000 dilution (mut/wt). For complete suppression of wild-type DNA amplification, raising amounts of PNA were used. In the presence of a PNA concentration of 2.5 *μ*[M]{.smallcaps} in the assay (curve 8), only the mutant-specific peak was observed comparable to curve 3 of the mutation-specific peak. Lower concentrations of PNA show a weak shoulder at the wild-type-specific melting temperature (curves 5--7; arrow), indicating incomplete suppression of the wild-type DNA amplification. Under these conditions, quantification of mutant DNA is impossible. It should be noted that higher PNA concentrations lead to a decrease of the efficiency of DNA amplification and therefore lowers fluorescence intensities (data not shown).

Determination of the sensitivity of the assay and quantification of mutated DNA
-------------------------------------------------------------------------------

To determine the sensitivity of our assay, serially an equivalent of 2--20 000 tumour cells of the colon carcinoma cell line SW 480, which bear the codon 12 mutation glycine (GGT) to valine (GTT) homozygous, were mixed each with 2 000 000 normal peripheral blood cells from a healthy subject. After DNA extraction, one-tenth of the eluted DNA was analysed. As seen in [Figure 3A](#fig3){ref-type="fig"}, an equivalent of two mutated cells can be detected in the presence of genomic DNA of an equivalent of 200 000 wild-type cells, which corresponds to a sensitivity of 1 to 5 : 100 000. The melting temperatures for wild-type and mutated DNA are 68.6 and 71.2°C, respectively. Additionally, the same dilution experiments were performed using enriched *BstN*I RFLP/PCR ([Mora *et al*, 1998](#bib22){ref-type="other"}). After gel electrophoresis of the amplified products, the mutant allele (143-bp band) and wild-type allele (114-bp band) could be visualised after ethidium bromide staining. The detection limit of the mutation was 10^−3^ (data not shown). Another favourite advantage of our real-time PCR technology is the quantification of mutated DNA simultaneously, if the amplification of the wild-type DNA was completely suppressed as seen in [Figure 3A](#fig3){ref-type="fig"}. After analysing the crossing points by the LightCycler software ([Figure 3B](#fig3){ref-type="fig"}, upper panel), the regression line was linear (slope=−2.878; *r*=−0.99) in the range of 4--40 000 copy numbers of mutated DNA in the background of 400 000 copies of wild-type DNA ([Figure 3B](#fig3){ref-type="fig"}, lower panel).

Genotyping of pancreatic tissue samples
---------------------------------------

Melting point analysis of amplification products was performed on five tissue samples of four patients. Patient no. 2 and 3 ([Figure 4](#fig4){ref-type="fig"}, curves 4 and 5) revealed a melting temperature of 72.1°C corresponding to a valine mutation in codon 12 of the DNA. Two different tissue samples (A and B) of patient no. 4 ([Figure 4](#fig4){ref-type="fig"}, curves 6 and 7) showed a melting point of 68.5°C representing a mutation other than valine. Further verification of this point mutation was not done. Complete suppression of amplification of wild-type DNA is demonstrated in [Figure 4](#fig4){ref-type="fig"} (curve 16) using a ratio of mutant to wild-type DNA of 1 to 10 000. In the presence of the wild-type specific PNA, an additional tissue sample of patient no. 1 ([Figure 4](#fig4){ref-type="fig"}, curve 3) was analysed and no fluorescence signal was detected, indicating the wild-type allele. All DNAs were tested by amplification without PNA, first.

Genotyping of plasma samples of patients with pancreatic cancer
---------------------------------------------------------------

Adequate amounts of DNA were extracted from 64 plasma samples of 10 patients (seven male, three female) with pancreatic cancer and three healthy subjects. Blood samples were obtained at least monthly over a period up to 13 months. To determine the amount of DNA per assay, real-time PCR was performed in the absence of PNA (data not shown). Owing to the low amount of extractable plasma DNA, we were able to use approximately 0.5 ng per assay. The PCR method using PNA-mediated PCR-clamping and hybridisation probes showed that the plasma samples of the three healthy control cases were negative for Ki-ras mutations as no fluorescence signals were detectable in the presence of wild-type-specific PNA. Ki-ras alterations were found in DNAs from 18 out of 64 (28%) plasma samples of four out of 10 patients with ductal adenocarcinoma of the pancreas. The mutation from glycine to valine was the predominantly detected gene alteration (15 out of 18; 83%). Other mutations were not further analysed.

Data synopsis of patients investigated is summarised in [Table 1](#tbl1){ref-type="table"}. The median was 11.5 months (5--83 months) after diagnosis. Two patients were suitable for surgical therapy. Among all patients metastases were detectable during tumour staging.

Time course analysis of the different clinical samples is shown in [Table 2](#tbl2){ref-type="table"} in context with serum levels of the tumour marker CA 19-9, pharmacological treatments and tumour imaging.

Out of the 10 patients investigated, four patients became positive during clinical observation with respect to Ki-ras mutation (nos. 11, 34, 39, 43). In all these cases, the mutated DNA was steadily detected until death of the patients in association with tumour progression and raising CA 19-9 serum levels (\>10^4^ U ml^−1^). The altered Ki-ras gene was not detected in patient no. 40, while CA 19-9 level was slightly elevated.

Three patients (nos. 13, 16, 38) show raising tumour marker values along with progressive disease, but no mutation was detectable in plasma samples. Patients nos. 29 and 37 showed progressive disease, while CA 19-9 values were low and no Ki-ras gene alterations were found.

DISCUSSION
==========

Our aim was to establish an assay for the detection of the hot spot mutation in codon 12 of the Ki-ras gene in plasma samples using PNA-mediated PCR-clamping and mutant-specific hybridisation probes. In contrast to [Thiede *et al* (1996)](#bib38){ref-type="other"}, where in case of mutant DNA the PCR primer outcompete the wild-type specific PNA, we used wild-type PNA (17-mer) and mutant-specific fluorescent-labelled hybridisation probes. Owing to the higher thermal instability of mutant DNA and wild-type-specific PNA hybrids, the detected fluorescence signal corresponds to the amplified mutant DNA and can be analysed by subsequent melting curve analysis.

Ki-ras mutations were analysed in a multitude of clinical specimens like fine-needle aspirates, stool, pancreatic and duodenal juice, blood cells, serum and plasma ([Minamoto *et al*, 2000](#bib20){ref-type="other"}) with high specificity (up to 100%) and a wide spectrum of sensitivities in the range of 27--100% ([Mulcahy *et al*, 1998](#bib24){ref-type="other"}; [Castells *et al*, 1999](#bib4){ref-type="other"}; [Li *et al*, 2004](#bib16){ref-type="other"}). Owing to the retroperitoneal position of the pancreas, tissue samples are difficult to obtain. Therefore, analysis of clinical samples easy and noninvasive to obtain like plasma would make molecular diagnosis easier, especially in earlier stages of pancreatic cancer and follow-up investigations. The origin of mutated plasma DNA of patients with malignant neoplasm is uncertain but due to the same gene alterations as the primary tumour it is likely that lysed tumour cells are the origin of naked DNA ([Castells *et al*, 1999](#bib4){ref-type="other"}). The analysis of tumour cells in peripheral blood is difficult because of the rareness of neoplastic cells. Furthermore, large amounts of nonmutated leucocytes mask the vestiges of mutated cells.

We restricted our point mutation analysis to one of the preferred glycine (GGT) to valine (GTT) variant as described in literature ([Anker *et al*, 1997](#bib1){ref-type="other"}), but our method allows the detection of the other gene alterations at codon 12 (aspartic acid, arginine and cysteine), too. The applicability of this method, first of all the correlation of detected gene mutations with clinicopathological findings, was evaluated by subsequent time course analysis of circulating non-cell-associated DNA in peripheral blood of patients with pancreatic cancer. The occurrence of Ki-ras gene mutations in primary pancreatic tumours is well known from literature ([Tada *et al*, 1993](#bib45){ref-type="other"}; [Sorenson *et al*, 1994](#bib44){ref-type="other"}; [Mulcahy *et al*, 1998](#bib24){ref-type="other"}). We also could detect Ki-ras gene mutations in selected tissue samples of the pancreas using our assay.

The sensitivity of our assay revealed a value of 0.001% being the highest compared with other methods for genotyping like ASA-PCR and RFLP-PCR reaching sensitivities in the range of 1.0--0.001% ([Jacobson and Mills, 1994](#bib12){ref-type="other"}; [Rhodes *et al*, 1997](#bib28){ref-type="other"}). Furthermore, the rapid cycle PCR enables quantification of the mutant DNA simultaneously if the fluorescence signal of the wild-type DNA is completely suppressed by binding of the PNA.

Quantification of mutant-type Ki-ras gene in plasma samples is inappropriate due to the low amount of DNA and the absence of cellular equivalents which allows the quantification of single copy genes as a reference. This method allows a very fast detection of Ki-ras point mutations (∼1 h) after DNA preparation from clinical samples. As no post-PCR handling is necessary, the possibility of contamination is minimised, which contributes to reduce false positive results.

While all previous studies only analysed one sample per individual after diagnosis of pancreatic cancer, we present a preliminary study of time course analysis of Ki-ras gene alterations. Thus, occurrence of mutations in samples analysed in our study can hardly be compared with incidences found by other investigators ([Mulcahy *et al*, 1998](#bib24){ref-type="other"}; [Castells *et al*, 1999](#bib4){ref-type="other"}; [Dianxu *et al*, 2002](#bib5){ref-type="other"}; [Maire *et al*, 2002](#bib18){ref-type="other"}). The percentages of plasma samples with mutated Ki-ras gene found to date in the existing studies differ in a wide range of 27--81%, which might reflect collection of samples at different tumour stages and various sensitivities of the assays for detection of Ki-ras point mutations. [Dianxu *et al* (2002)](#bib5){ref-type="other"} tested 37 of 41 patients (90.2%) with pancreatic cancer positive when plasma Ki-ras mutation analysis was combined with elevated CA 19-9 serum levels (\>37 Units ml^−1^). In our study, we detected Ki-ras mutant alleles only in four out of 10 patients with high CA 19-9 levels. These differences might be due to different sensitivities of the detection methods, even though the sensitivity of our method was the highest compared to the others. In general, more clinical samples of patients with pancreatic cancer, chronic pancreatitis and healthy individuals have to be analysed for determination of sensitivity, specificity, negative and positive predictive values of the assay presented in this study. Owing to the limited number of patients analysed, a correlation of the detectable Ki-ras mutations with clinicopathological findings and pharmacological treatments is certainly prematurely, but we can demonstrate the potential of the rapid cycle PCR in the presence of wild-type PNA and mutation-specific hybridisation probes for detection of point mutations.

We could identify Ki-ras-mutated alleles by this rapid real-time PCR at late stages of carcinogenesis very well and may contribute to therapeutic regimes and clinical practice.

We thank Monika Seifert for excellent technical work, our study nurses who cared for patients and Miriam Peet for carefully reading the manuscript.

![Relative positions and orientations of PCR primers (ki-ras F; ki-ras R), hybridisation probes (12val sensor; ki-ras anchor) and the wild-type peptide nucleic acid (PNA-17) for detection of codon 12 mutation of the Ki-ras proto-onkogene (Genbank accession no. K01519; nucleotid positions 1--164).](92-6602319f1){#fig1}

![Titration of PNA concentrations for complete suppression of amplification of 1 *μ*g of wild-type DNA (WT DNA; human placenta DNA) in the presence of 100 pg of mutated DNA (10 000 : 1) extracted from cells of the colon carcinoma cell line SW 480, which bears the codon 12 mutation of the Ki-ras proto-oncogene (GGT to GTT; glycine to valine) homozygous. After rapid cycle amplification of the DNA in the presence of the valine mutation-specific hybridisation probes, the melting curves were analysed by the LightCycler software (version 3.5). Temperature transition rate was 0.3°C s^−1^. 1: non template control (NTC); 2: 1 *μ*g wild-type (WT) DNA without PNA; 3: 100 pg Val DNA without PNA; 4: 1 *μ*g WT DNA/100 pg Val DNA without PNA; 5--8: 1 *μ*g WT DNA/100 pg Val DNA each with raising concentrations of PNA as indicated. PCR experiments were performed twice.](92-6602319f2){#fig2}

![Titration of assay sensitivity. (**A**) Sensitivity of melting point analyses using mutant-specific hybridisation probes and wild-type specific PNA. Peripheral blood cells from a healthy donor (HD) and SW 480 colon carcinoma cells, which bear the valine mutation homozygous (Val), were mixed as indicated and DNA was extracted by spin column technology. After rapid cycle amplification of the DNA in the presence of the valine mutation-specific hybridisation probes, the melting curves were analysed by the LightCycler software (version 3.5). Temperature transition rate was 0.3°C s^−1^. 1: nontemplate control (NTC); 2: WT DNA without PNA; 3: 2 × 10^4^ SW480+2 × 10^5^ WT; 4: 2 × 10^3^ SW480+2 × 10^5^ WT; 5: 2 × 10^2^ SW480+2 × 10^5^ WT; 6: 2 × 10^1^ SW480+2 × 10^5^ WT; 7: 2 × 10^0^ SW480+2 × 10^5^ WT. (**B**) Quantification of Val DNA in the presence of WT DNA. Serial diluted mixtures of constant amounts of wild-type DNA and varying amounts of Val DNA from cells as indicated (see [Figure 3A](#fig3){ref-type="fig"}) were plotted against *C*~t~ values (threshold cycle). Slope, *r* value and regression line are shown. PCR experiments were performed twice.](92-6602319f3){#fig3}

![Detection of Ki-ras point mutations in tissue samples. DNA from paraffin-embedded tissue samples of four different patients with pancreatic cancer were extracted by spin column technology after overnight digestion with proteinase K. After rapid cycle amplification of the eluted DNA in the presence of the valine mutation-specific hybridisation probes and wild-type-specific PNA, the melting curves were analysed by the LightCycler software (version 3.5). Temperature transition rate was 0.3°C s^−1^ in the range of 40--95°C. PCR experiments were performed twice. Melting temperatures (*T*~m~): wild-type DNA: 69.5°C, valine DNA 72.1°C and unknown mutation 68.5°C. 1: Nontemplate control (NTC); 2: 1 *μ*g wild-type DNA (WT) without PNA; 3--7: tissue samples of patients. From patient no. 4, two different samples (4A and 4B) were analysed; 16: 100 pg Val DNA/1 *μ*g WT DNA in the presence of PNA.](92-6602319f4){#fig4}

###### 

Patients and incidence of Ki-ras mutations in plasma DNA

  **No.**    **Sex**  **Age (years)**   **Tumour site**   **Tumour stage**   **Histological type**    **Surgery**  **Survival**   **WT**   **Mut**
  --------- --------- ----------------- ----------------- ------------------ ----------------------- ------------- -------------- -------- ---------
  11            M     67                NA                IVb                DAC                          No       9              2        5
  13            M     81                Head              Metastases         DAC                          No       6              5        0
  16            M     70                Head              IVb                NA                           No       35             10       0
  29            M     51                Head              Metastases         DAC (moderate)               No       5              3        0
  34            M     50                Head              Metastases         DAC (poorly)                 No       8              3        3
  37            F     69                Head              T2, N1, M1         NA                           No       23             9        0
  38            F     57                Head              Metastases         DAC (moderate)               No       6              4        0
  39            M     59                Head              Metastases         DAC (moderate)               Yes      83             1        1
  40            F     71                Head              T3, N1, M1         DAC (moderate/poorly)        Yes      43             9        0
  43            M     52                Head              Metastases         DAC (moderate)               No       14             0        9

DAC=ductal adenocarcinoma; NA=data not available; Survival=survival in months after diagnosis; WT=wild-type (number of samples); Mut=mutation (number of samples).

###### 

Association with clinicopathological findings

                      **Months after first sample**                                                                                                                                                  
  ------------------ ------------------------------- --------- --------- --------- --------- --------- --------- --------- ------------------------------------ --------- --------- --------- ------ -----
  No. 11FS 3Ex 10                  Gly                  Gly     **Val**    *NA*     **Val**   **Val**   **Val**   **Val**        ←Ki-ras status in plasma                                               
                                  2654                 2706      5288     \>10^4^    8077       NA      \>10^4^             ←CA 19-9 level in serum (U ml^−1^)                                          
                                   GFF                  GFF       Tax       Tax       Tax       Tax       Tax       Tax             ←(Chemo-) therapy                                                   
                                   NC                             PD                                                                     ←Imaging                                                       
  No. 13FS 0Ex 7                   Gly                  NA        Gly      *NA*       Gly       Gly       Gly                                                                                           
                                  6879                  NA        698       654      2254     \>10^4^   \>10^4^                                                                                         
                                   Gem                  Gem       Gem       Gem       Gem       Gem       OFF                                                                                           
                                                                            PR                  PD                                                                                                      
  No. 16FS 22Ex 35                 Gly                 *NA*       Gly      *NA*       Gly      *NA*       Gly       Gly                    Gly                     Gly       Gly      *NA*     Gly    Gly
                                   109                  62        43        NA        45        90        NA        191                    340                     426      1948       NA      4216   NA
                                   OFF                  OFF       OFF       OFF       OFF       OFF       OFF       OFF                    OFF                     OFF       OFF       OFF     Gem    Gem
                                                                            NC                                      NC                                                                          PD      
  No. 29FS 2Ex 5                   Gly                  Gly       Gly      *NA*                                                                                                                         
                                    1                   NA         9        32                                                                                                                          
                                   Gem                  OFF                 OFF                                                                                                                         
                                   PD                                       PD                                                                                                                          
  No. 34FS 1Ex 8                   Gly                 *NA*       Gly       Gly     **Mut**   **Mut**   **Mut**                                                                                         
                                  5916                 2291      4169     \>10^4^   \>10^4^   \>10^5^     NA                                                                                            
                                   Gem                  Gem       Gem       Gem       Gem       OFF       OFF                                                                                           
                                                                  PR                  PD                                                                                                                
  No. 37FS 11Ex 23                 Gly                  NA        Gly       NA        Gly       Gly       Gly       Gly                    Gly                     Gly       Gly                        
                                    7                   NA        13        NA        28        37        NA        41                      50                     52        56                         
                                   Tax                  Tax       Tax       Tax       Tax       Tax       Tax       Tax                    Tax                     Tax       Tax                        
                                                                                                                                                                                                     
  No. 38FS 1Ex 5                   Gly                  Gly       Gly       Gly                                                                                                                         
                                 \>10^6^              \>10^6^     NA      \>10^6^                                                                                                                       
                                   Gem                  Gem       OFF       OFF                                                                                                                         
                                                                  PD                                                                                                                                    
  No. 39FS 82Ex 83                 Gly                **Val**                                                                                                                                           
                                 \>10^4^              \>10^4^                                                                                                                                           
                                   Gem                  Gem                                                                                                                                             
                                   PD                                                                                                                                                                   
  No. 40FS 31Ex 43                 Gly                 *NA*       NA        Gly      *NA*       Gly       Gly       Gly                    Gly                     Gly       Gly      *NA*     Gly      
                                   NA                   NA        309       NA        NA        464       NA        179                     NA                     NA        218       NA      251      
                                   Gem                  Gem       Gem       Gem       OFF                                                  Tax                     Tax       Tax                        
                                                                            PD                                                                                                                          
  No. 43FS 1Ex 14                **Val**               *NA*      *NA*     **Val**   **Val**   **Val**   **Val**   **Val**                **Val**                 **Val**   **Val**    *NA*     *NA*     
                                   677                  NA        434      1365      2116      5231       883       446                    544                    1506     \>10^4^   \>10^4^            
                                   GFF                  GFF       GFF       GFF       GFF       Tax       Tax       Tax                    Tax                     Tax       Tax                        
                                                                            PD                                                              PR                                                          
                                                                                                                                                                                                     

FS=time of 1st collected sample after diagnosis (in months); Ex=death in months after collection of the 1st sample; NA=no data available; Gly=glycine (wild type); Val=valine (mutation); Mut=mutation different from valine; GFF=gemcitabine+5-fluorouracil+folinic acid; Gem=gemcitabine mono; Tax=taxol; OFF=oxaliplatin+5-fluorouracil+folinic acid; NC=no change; PD=progressive disease; PR=partial regression.
